ArticleStem cell reports2018
Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control.
Article in Stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 78 citations in OpenAlex.
- Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint.Stem cells translational medicine · 2026Article
- Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations.Stem cell reports · 2026Review
- Truncated CD19 as a selection marker for the isolation of stem cell-derived β-cells.Disease models & mechanisms · 2026Article
- Differentiation of Human Pluripotent Cells into Pancreatic Beta Cells for Disease Modeling and Cell Replacement Therapy for Diabetes.International journal of molecular sciences · 2025Review
- New frontiers in type I diabetes treatment: the impact of mesenchymal stromal cells on long-term complications.Frontiers in clinical diabetes and healthcare · 2025Review
- Identification and removal of unexpected proliferative off-target cells emerging after iPSC-derived pancreatic islet cell implantation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Encapsulation and immune protection for type 1 diabetes cell therapy.Advanced drug delivery reviews · 2024Review
- CDK8/19 inhibition plays an important role in pancreatic β-cell induction from human iPSCs.Stem cell research & therapy · 2023Article
- A glucose-blue light AND gate-controlled chemi-optogenetic cell-implanted therapy for treating type-1 diabetes in mice.Frontiers in bioengineering and biotechnology · 2023Article
- A Mini-Review of Current Treatment Approaches and Gene Therapy as Potential Interventions for Diabetes Mellitus Types 1.Advanced biomedical research · 2023Review
- Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC.Scientific reports · 2022Article
- Engineering islets from stem cells for advanced therapies of diabetes.Nature reviews. Drug discovery · 2021Review
- A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes.Science translational medicine · 2021Article
- Applications of iPSC-derived beta cells from patients with diabetes.Cell reports. Medicine · 2021Review
- Functional maturation of immature β cells: A roadblock for stem cell therapy for type 1 diabetes.World journal of stem cells · 2021Review
- Building Biomimetic Potency Tests for Islet Transplantation.Diabetes · 2021Review
- A Stem Cell Approach to Cure Type 1 Diabetes.Cold Spring Harbor perspectives in biology · 2021Review
- Engineering precision therapies: lessons and motivations from the clinic.Synthetic biology (Oxford, England) · 2021Review
- Human Pluripotent Stem Cells to Model Islet Defects in Diabetes.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human stem cells represent a potential source for implants that replace the depleted functional beta cell mass (FBM) in diabetes patients. Human embryonic stem cell-derived pancreatic endoderm (hES-PE) can generate implants with glucose-responsive beta cells capable of reducing hyperglycemia in mice. This study with device-encapsulated hES-PE (4 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.